Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
To provide treatment to eligible subjects who have successfully completed one of the
following phase III ziprasidone studies, A1281028, A1281044, A1281045 (NCT00136994) or
A1281088 (NCT00143351).
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.